Gene single nucleotide polymorphism accumulation improves survival in advanced head and neck cancer patients treated with weekly paclitaxel.
case_control · Level III
Where this comes from
- Record sourced from PubMed, PMID 19504558.
- Also identified by DOI 10.1002/lary.20254.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Single nucleotide polymorphisms (SNPs) of certain genes involved in drug metabolism correlate with survival. We evaluated the presence of SNPs in six genes (CYP2C8, GSTT1, GSTP1, MDR1-57, MDR1-62, and ERCC1) and the response rate (RR), time to progression (TTP), and overall survival (OS) of advanced head and neck cancer patients treated with weekly paclitaxel. SNPs in CYP2C8, MDR1-57, and MDR1-62 genes were more frequent than wild-type genes in our patients. RR was 45% (21/47), and median TTP in responders was 5.1 months. OS for all patients was 5.6 months. Response was higher in SNPs of MDR1-62, MDR1-57, or in two or more accumulated genes than in those with wild-type genes. OS was significantly longer in patients with two or more accumulated SNPs (P = .039). Response rate and OS were significantly higher in patients with two or more accumulated SNPs.
Medical subject headings
- Genetic Markers
- Head and Neck Neoplasms
- Paclitaxel
- Palliative Care
- Polymorphism, Single Nucleotide